The authors describe the pregnancy and outcome in two women with MS using natalizumab. The first patient used it in the periconceptional period, and the second patient used it in both the periconceptional period and throughout gestation. The course of the first patient was complicated by an exacerbation of MS. The second patient did not experience MS relapses during pregnancy, while still using natalizumab. Importantly, the newborns did not show any abnormalities postnatal and at 6 weeks’ follow-up.
“Reassuring, but not enough data to commit to using Natalizumab throughout pregnancy.”